HPV Genotyping PCR: Primer Design for High-Risk HPV Detection

HPV Genome and Diagnostic Targets

Over 200 HPV types, ~14 classified as high-risk (HR-HPV) for cervical cancer. HPV 16 and 18 account for ~70% of cervical cancers worldwide. For PCR, the primary target is the L1 capsid gene (most conserved). Secondary targets include E6 and E7 oncogenes, retained in all HPV-associated cancers.

Consensus HPV Primers (L1 Gene)

MY09/MY11 and PGMY: Degenerate primer pools with up to 18 different primers covering L1 sequence diversity. Amplify ~450 bp region.

GP5+/GP6+: Single primer pair with limited degeneracy amplifying ~150 bp of L1. Better for degraded DNA from clinical specimens.

Using established systems is recommended over de novo design. Use the VigyanLLM Primer tool to verify coverage across HPV types.

Type-Specific HPV Primers (E6/E7)

E6/E7 genes are retained and expressed in all HPV-driven cancers. These genes are more variable across types, enabling type-specific amplification. Validate against known SNP positions within each HPV type. Integration breakpoints: E6 is nearly always intact; E7 may be partially deleted.

Multiplex HPV Genotyping Assays

Approaches include type-specific multiplex PCR (5–7 primer pairs with different amplicon sizes), Luminex bead-based genotyping (consensus L1 PCR + type-specific probe hybridisation detecting up to 27 types), qPCR with type-specific probes, and MassArray (mass spectrometry-based genotyping).

Validation of HPV Primers

Test against purified plasmid DNA from all high-risk and at least 10 low-risk HPV types. Determine LOD using HPV-positive cell lines (e.g., SiHa for 16, HeLa for 18) — target <100 copies per reaction. Test against a clinical panel of 100+ samples. Confirm no cross-reactivity with Chlamydia, Neisseria, Trichomonas, Candida, and human genomic DNA. Intra- and inter-run CV should be <10%.